Form 4: Akero Therapeutics COO Jonathan Young Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Akero Therapeutics' Chief Operating Officer, Jonathan Young, sold 2,516 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.
Summary
- Jonathan Young, the Chief Operating Officer of Akero Therapeutics, sold 2,516 shares of common stock on June 11, 2024.
- The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
- The shares were sold at a weighted-average price of $22.641, with individual transactions ranging from $22.640 to $22.760.
- Following the transaction, Young directly owns 250,790 shares of Akero Therapeutics common stock.
- Young also has indirect ownership of 60,000 shares held in irrevocable trusts for the benefit of his children.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing a stock sale for tax purposes. It doesn't convey any particularly positive or negative sentiment about the company's prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This sale appears to be routine, covering tax obligations, and doesn't necessarily indicate a change in Young's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 06/11/2024 | Date of stock sale transaction |
| 06/13/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.